Takeda Pharmaceutical Co Ltd (SSE:4502)
円 4300 0 (0%) Market Cap: 6.48 Til Enterprise Value: 10.85 Til PE Ratio: 45.22 PB Ratio: 0.89 GF Score: 76/100

Arrowhead Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd Collaboration and Licensing Agreement to Develop ARO-AAT Conference Call Transcript

Oct 08, 2020 / 12:30PM GMT
Release Date Price: 円3675
Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions) I will now hand the conference over to your speaker today, Mr. Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - VP of IR

Thank you, Justin, and good morning, everyone. We're happy to announce today that Arrowhead and Takeda have signed an agreement whereby the 2 companies will co-develop and co-commercialize Arrowhead's investigational ARO-AAT candidates against Alpha-1 liver disease.

Our President and CEO, Dr. Christopher Anzalone, will provide an overview of the deal. James Hassard, our Chief Commercial Officer, will discuss why we think Takeda is the ideal partner for ARO-AAT. And Dr. Asit Parikh, Head of Takeda's Gastroenterology Therapeutic Area unit will talk about why they are excited about ARO-AAT. We will then open up the call to your questions.

Also with us today for the Q&A portion of the call are: Ken Myszkowski, our Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot